Pioneering a new class of treatments for neuro-visual disorders.

Around 15 million Americans suffer from vision loss caused by deficiencies in the brain, instead of any structural issues with the eyes. Traditional therapeutic modalities are unable to properly target and treat these deficits, leaving a significant unmet need.
Scroll to learn more
By harnessing the latest in digital technology, we're creating an entirely new category of medicines to address these conditions. We develop software products that generate therapeutic visual stimuli and deliver them to the patient through a virtual reality headset, using the eyes to stimulate the brain. The success of our amblyopia therapeutic provides proof-of-concept for our broader platform.
Development Pipeline
Luminopia clinical development pipeline in neuro-visual disorders
In The News
Press Releases
Follow along with our latest news. For press inquiries, please contact
Leadership Team
To achieve our mission, we've brought together a world-class team with deep experience and a true passion for helping patients.
Brion Raymond
  • Former CCO at Clearside Biomedical
  • Former Director at Genentech
Drew Mowery
Sr Director, Commercial Strategy
  • Former Sr Director at Ultragenyx Pharmaceutical
  • Former Director at bluebird bio and Genentech
Endri Angjeli
VP of Clinical Development
  • Former Director at Ora
  • Biomedical Engineer
Hank Wu
  • Former VP of Digital at Evelo Biosciences
  • Former Director at Biogen
Katrina Moseley Journey
VP of Commercial
  • Former GM of Dompe Canada
  • Former Sr. Director Clearside Biomedical and Santen
Scott Xiao
Co-Founder and CEO
  • MIT TR Innovators Under 35
  • Forbes 30 Under 30
Shelley Hancock
Sr Director, Medical Affairs
  • Former Sr Director, Medical & Professional Affairs at Clearside Biomedical
Stephanie Roberts
Head of Market Access
  • Former Sr Director, National Accounts at Akili
  • Former National Accounts Director at Otsuka and Acorda
Sunny Atwal
VP of Engineering
  • Former VP of Technology at Moth+Flame
  • Former SVP of Technology at Littlstar
Board of Directors
We're proud to have the support of an exceptional Board of Directors, with leaders from across healthcare, tech, and entertainment.
Photo of Casey Tansey
Casey Tansey
  • General Partner at USVP
  • Former CEO at Epicor Medical, Heartport
Photo of Dean Travers
Dean Travers
  • Co-Founder
  • Thiel Fellow
  • Forbes 30 Under 30
Photo of Mark Jacobstein
Mark Jacobstein
  • Executive Business Advisor at Immunai
  • Former CUEO at Guardant Health
Photo of Robert Langer
Robert Langer, ScD
  • Institute Professor at MIT
  • Co-Founder of Moderna
  • Most cited engineer in history
Photo of Scott Xiao
Scott Xiao
  • CEO
  • MIT TR Innovators Under 35
  • Forbes 30 Under 30
Photo of William Dai
William Dai
  • Founding Managing Partner at ShangBay Capital
  • Former CFO at Boston Scientific China
We're grateful to have the backing of several top-tier investment firms who share our vision for the future.
Platform Scientific Advisors
We're thrilled to have a group of renowned clinicians and scientists guiding the development of our platform.
Peter J. McDonnell, MD
Director, Professor Of Ophthalmology
The Wilmer Eye Institute
Marguerite McDonald,MD, FACS
Director, Professor Of Ophthalmology
New York University Langone Medical Center
Peter Bex, PhD
Chair Of Psychology
Northeastern University
Krystel Huxlin, PhD
Professor Of Ophthalmology
University of Rochester
Eric Singman, MD
Professor Of Ophthalmology
University of Maryland
The following Luminopia products, either alone or in combination with other products, are protected by one or more of the identified patents. The absence of a product name or patent number associated with any listed product does not constitute a waiver of Luminopia’s intellectual property rights concerning that product. This page is intended to serve as notice under 35 U.S.C. § 287(a).
U.S. Patents, Pending U. S. Applications, and Foreign Counterparts
US 8,454,166
US 8,807,749

US 8,820,930
US 11,826,098